Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial-Reference-Cited by-同舟云学术

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

Published:2018-04 Issue:4 Volume:19 Page:497-509
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Loibl Sibylle,O'Shaughnessy Joyce,Untch Michael,Sikov William M,Rugo Hope S,McKee Mark D,Huober Jens,Golshan Mehra,von Minckwitz Gunter,Maag David,Sullivan Danielle,Wolmark Norman,McIntyre Kristi,Ponce Lorenzo Jose J,Metzger Filho Otto,Rastogi Priya,Symmans W Fraser,Liu Xuan,Geyer Charles E

Publisher

Elsevier BV

Subject

Oncology

Reference25 articles.

1. Neoadjuvant therapy in breast cancer as a basis for drug approval;Berry;JAMA Oncol,2015

2. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis;Cortazar;Lancet,2014

3. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes;von Minckwitz;J Clin Oncol,2012

4. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes;Masuda;Clin Cancer Res,2013

5. Current approaches in treatment of triple-negative breast cancer;Wahba;Cancer Biol Med,2015

Cited by 580 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Can we counterbalance restricted access to innovation through specialized breast cancer care? The REAL-NOTE study;The Breast;2024-12

2. Real-world prevalence, treatment and survival of “high risk” early breast cancer, with mandatory testing of gBRCA1/2 mutation according to the OlympiA trial inclusion criteria: Data from a population-based registry;The Breast;2024-12

3. BRCA genetic testing and counseling in breast cancer: how do we meet our patients’ needs?;npj Breast Cancer;2024-09-05

4. BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing;British Journal of Cancer;2024-08-30

5. The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models;Genome Medicine;2024-08-26